Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

August 01, 2006 (Vol. 26, No. 14)

Facilitating the Manufacturing of Oligos

Prime Synthesis Develops Consumable Products in Therapeutic and Research Quantities

  • The approval of Macugen for the treatment of age-related macular degeneration by the FDA in December 2004 marked the introduction of the first commercially successful oligonucleotide therapeutic to the marketplace. Macugen contains a substituted RNA that specifically binds a protein that plays a critical role in the disease ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.